Background: Alzheimer's disease (AD) is the most common type of dementia globally and is the fifth leading cause of death and disability. About half of all people suffering from the disease are living in sub-Saharan African Countries including Kenya. However, research on dementia has been almost exclusively focused on the Global North societies. In Kenya, little is known about patients' lived experiences with AD.
Objective: To explore patient's experiences living with and managing Alzheimer's disease in Kenya.
Method: We employed ethnographic methods encompassing clinical and home observations and lengthy interviews among people with early-stage Alzheimer's disease (n = 30) in Kenya. Patients were purposively recruited from the neurology clinic at the Aga Khan University Hospital in Nairobi. We also conducted 10 home visits to understand existing social support systems and self-management practices. Field notes and qualitative interviews were transcribed and analyzed verbatim with use of QSR NVivo 12 software.
Result: Two-thirds of the patients were aged 50 years and above, had low education levels and fully depended on close family members for support. Patients experienced challenges such as higher cost of hospital care and treatment, comorbidities (e.g., depression, diabetes and hypertension), language barrier, forgetfulness, being misunderstood and conflicts with loved ones. These challenges made managing their AD difficult. Social connectedness - which entailed: (i) Self-connectedness - including active participation in self-care, relaxation and having personal time; and (ii) Connectedness with others (e.g., relationships with family, friends to prevent loneliness and isolation) were found to be key on how patients managed and coped with their Alzheimer's disease.
Conclusion: People living with AD in Kenya cannot be understood without knowing about their inner lives, other people around them and the background where they belong. Alzheimer's disease can transform people's self-identities but with good social support system, patients can live quality lives. There is a need to train family members and other informal caregivers to improve care and foster a sense of belonging amongst the patients. More research on Alzheimer's disease in Kenya is needed as well as increased public awareness and community sensitization regarding dementias.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.090377 | DOI Listing |
Adv Sci (Weinh)
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
β-secretase (BACE1) is instrumental in amyloid-β (Aβ) production, with overexpression noted in Alzheimer's disease (AD) neuropathology. The interaction of Aβ with the receptor for advanced glycation endproducts (RAGE) facilitates cerebral uptake of Aβ and exacerbates its neurotoxicity and neuroinflammation, further augmenting BACE1 expression. Given the limitations of previous BACE1 inhibition efforts, the study explores reducing BACE1 expression to mitigate AD pathology.
View Article and Find Full Text PDFActa Neuropathol Commun
January 2025
Department of Biological Sciences, Purdue University, 915 Mitch Daniels Blvd, West Lafayette, IN, USA.
Dementia refers to an umbrella phenotype of many different underlying pathologies with Alzheimer's disease (AD) being the most common type. Neuropathological examination remains the gold standard for accurate AD diagnosis, however, most that we know about AD genetics is based on Genome-Wide Association Studies (GWAS) of clinically defined AD. Such studies have identified multiple AD susceptibility variants with a significant portion of the heritability unexplained and highlighting the phenotypic and genetic heterogeneity of the clinically defined entity.
View Article and Find Full Text PDFNeurotherapeutics
January 2025
Department of Biochemistry, University of Alberta, Edmonton, Alberta, T6G 2H7, Canada. Electronic address:
Amyloidogenic protein aggregation is a pathological hallmark of Alzheimer's Disease (AD). As such, this critical feature of the disease has been instrumental in guiding research on the mechanistic basis of disease, diagnostic biomarkers and preventative and therapeutic treatments. Here we review identified molecular triggers and modulators of aggregation for two of the proteins associated with AD: amyloid beta and tau.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
First Operating Room, The First Hospital of Jilin University, Changchun, China. Electronic address:
Background: Certain peripheral proteins are believed to be involved in the development of Alzheimer's disease (AD), but the roles of other new protein biomarkers are still unclear. Current treatments aim to manage symptoms, but they are not effective in stopping the progression of the disease. New drug targets are needed to prevent Alzheimer's disease.
View Article and Find Full Text PDFNeuroscience
January 2025
Departamento de Genómica, Instituto de Investigaciones Biológicas Clemente Estable, MEC, Av. Italia 3318, Montevideo, CP 11600, Uruguay; Departamento de Biología Celular y Molecular, Facultad de Ciencias, Universidad de la República, Iguá, Montevideo, 4225, CP 11400, Uruguay. Electronic address:
Local protein synthesis (LPS) in axons is now recognized as a physiological process, participating both in the maintenance of axonal function and diverse plastic phenomena. In the last decades of the 20th century, the existence and function of axonal LPS were topics of significant debate. Very early, axonal LPS was thought not to occur at all and was later accepted to play roles only during development or in response to specific conditions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!